The current guidelines advise against using β-blockers in PAH patients [58]; however, a synergistic interaction between PGI2 and β-AR pathways suggests further research is required to understand if any PAH patient subgroup might benefit from β-blockers. The gene discussed is ADRB2; the disease is pulmonary arterial hypertension.